Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Ceftaroline applications for therapy in the United States.

Corey GR, Jones RN.

Clin Infect Dis. 2012 Sep;55 Suppl 3:S171-2. doi: 10.1093/cid/cis558. No abstract available.

PMID:
22903948
2.

Ceftaroline: a comprehensive update.

Kaushik D, Rathi S, Jain A.

Int J Antimicrob Agents. 2011 May;37(5):389-95. doi: 10.1016/j.ijantimicag.2011.01.017. Epub 2011 Mar 21. Review.

PMID:
21420284
3.

Cefepime and mortality: a real issue?

Mebis J, Goossens H, Berneman ZN.

Scand J Infect Dis. 2010 Jul;42(6-7):545-8. doi: 10.3109/00365540903555349.

PMID:
20144128
4.

Spectracef. New cephalosporin antibiotic approved.

[No authors listed]

Nursing. 2002 Feb;32(2):20. No abstract available.

PMID:
11924162
5.

Summary of ceftaroline fosamil clinical trial studies and clinical safety.

File TM Jr, Wilcox MH, Stein GE.

Clin Infect Dis. 2012 Sep;55 Suppl 3:S173-80. doi: 10.1093/cid/cis559. Review.

PMID:
22903949
6.

Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.

Parish D, Scheinfeld N.

Curr Opin Investig Drugs. 2008 Feb;9(2):201-9.

PMID:
18246523
7.

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2009;69(7):809-31. doi: 10.2165/00003495-200969070-00003. Review.

PMID:
19441869
8.

Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.

Jones RN, Mendes RE, Sader HS.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv17-31. doi: 10.1093/jac/dkq252.

PMID:
21115451
9.

Cephalosporins drop nearly 8% in third quarter.

[No authors listed]

Hosp Mater Manage. 2008 Jan;33(1):9. No abstract available.

PMID:
18257428
10.

Ceftaroline fosamil: a new broad-spectrum cephalosporin.

Laudano JB.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii11-8. doi: 10.1093/jac/dkr095. Review.

PMID:
21482565
11.

Ceftaroline for complicated skin and skin-structure infections.

Nannini EC, Stryjewski ME, Corey GR.

Expert Opin Pharmacother. 2010 May;11(7):1197-206. doi: 10.1517/14656561003777026.

PMID:
20402556
12.

Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Saravolatz LD, Stein GE, Johnson LB.

Clin Infect Dis. 2011 May;52(9):1156-63. doi: 10.1093/cid/cir147. Review.

PMID:
21467022
13.

Plans to restrict 'extra-label' use of cephalosporins in the USA.

[No authors listed]

Vet Rec. 2012 Feb 11;170(6):142. doi: 10.1136/vr.e927. No abstract available.

PMID:
22331777
14.

Introduction: fusidic acid enters the United States.

Moellering RC Jr, Corey GR, Grayson ML.

Clin Infect Dis. 2011 Jun;52 Suppl 7:S467-8. doi: 10.1093/cid/cir171. No abstract available.

PMID:
21546622
15.

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.

Biek D, Critchley IA, Riccobene TA, Thye DA.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv9-16. doi: 10.1093/jac/dkq251. Review.

PMID:
21115457
16.

The United States Food and Drug Administration and the end of antibiotics.

Shlaes DM, Moellering RC Jr.

Clin Infect Dis. 2002 Feb 1;34(3):420-2. No abstract available.

PMID:
11774094
17.

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Jorgenson MR, DePestel DD, Carver PL.

Ann Pharmacother. 2011 Nov;45(11):1384-98. doi: 10.1345/aph.1Q225. Epub 2011 Oct 18. Review.

PMID:
22009993
18.

Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Poon H, Chang MH, Fung HB.

Clin Ther. 2012 Apr;34(4):743-65. doi: 10.1016/j.clinthera.2012.02.025. Epub 2012 Mar 22. Review.

PMID:
22444785
19.
20.

Ceftaroline (Teflaro): a new cephalosporin.

Belavic JM.

Nurse Pract. 2011 Nov;36(11):12-3. doi: 10.1097/01.NPR.0000406491.90252.29. No abstract available.

PMID:
22008594

Supplemental Content

Support Center